SCHEDULE 13G: Boothbay Fund Management Discloses 6% Stake in Forte Biosciences

Boothbay Fund Management, LLC and its Managing Member, Ari Glass, have disclosed a 6% beneficial ownership stake in Forte Biosciences, Inc. common stock.

Summary

• Boothbay Fund Management, LLC and Ari Glass, its Managing Member, have jointly filed a Schedule 13G, reporting beneficial ownership of Forte Biosciences, Inc. common stock.
• As of December 31, 2024, both reporting persons beneficially own 88,785 shares of Forte Biosciences, Inc. common stock.
• This ownership represents 6% of the total class of securities outstanding.
• The shares are held by one or more private funds managed by Boothbay Fund Management, LLC.
• The reporting persons have shared voting and shared dispositive power over the 88,785 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual regulatory disclosure of beneficial ownership, which is neutral in tone and does not contain performance-related information or explicit positive/negative statements about the company's operations or financial health.

Positives

• The disclosure of a 6% stake by an investment firm like Boothbay Fund Management may signal institutional confidence in Forte Biosciences, potentially attracting further investor interest.

Future Outlook

This document is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Forte Biosciences' future performance or operations.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities."

Industry Context

This filing represents a standard regulatory disclosure of a significant passive investment by an institutional fund in a publicly traded company, common within the financial and biotechnology sectors. It indicates an investment firm's position in a biotech company, which is a routine occurrence in the market.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor may influence market perception and potentially attract other investors, impacting share liquidity and price.

Key Dates

Keywords

Forte Biosciences, Boothbay Fund Management, Ari Glass, Schedule 13G, Beneficial Ownership, Common Stock, Investment Firm, Biotechnology